Cleavage of cystatin C is not associated with multiple sclerosis
Cleavage of cystatin C is not associated with multiple sclerosis
复制标题
DOI：
10.1002/ana.20968
复制
发表时间：
2007-08-01
影响因子：
11.2
通讯作者：
Urbani, Andrea
中科院分区：
文献类型：
--
作者：
Del Boccio, Piero;Pieragostino, Damiana;Urbani, Andrea
最近，Irani及其同事提出脑脊液中的C-末端切割的同种型半胱氨酸蛋白酶抑制剂C（12.5kDa）作为多发性硬化症的标志物。在这项研究中，我们证明，12.5kDa的产品的胱抑素C的前八个N-末端残基的降解形成。此外，这种降解在多发性硬化症的脑脊液中不是特异性的，而是由在-20 ℃下不适当的样品储存引起的。我们的结论是，使用的12.5kDa的产品的半胱氨酸蛋白酶抑制剂C在脑脊液中可能会导致一个错误的诊断多发性硬化症。分析前验证程序是蛋白质组学研究的强制性程序。
Recently, Irani and colleagues proposed a C-terminal cleaved isoform cystatin C (12.5kDa) in cerebrospinal fluid as a marker of multiple sclerosis. In this study, we demonstrate that the 12.5kDa product of cystatin C is formed by degradation of the first eight N-terminal residues. Moreover, such a degradation is not specific in the cerebrospinal fluid of multiple sclerosis, but rather is given by an inappropriate sample storage at -20 degrees C. We conclude that the use of the 12.5kDa product of cystatin C in cerebrospinal fluid might lead to a fallacious diagnosis of multiple sclerosis. Preanalytical validation procedure is mandatory for proteomics investigations.